PE20090950A1 - Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3

Info

Publication number
PE20090950A1
PE20090950A1 PE2008001865A PE2008001865A PE20090950A1 PE 20090950 A1 PE20090950 A1 PE 20090950A1 PE 2008001865 A PE2008001865 A PE 2008001865A PE 2008001865 A PE2008001865 A PE 2008001865A PE 20090950 A1 PE20090950 A1 PE 20090950A1
Authority
PE
Peru
Prior art keywords
diona
triazin
alkyl
dopamine
treatment
Prior art date
Application number
PE2008001865A
Other languages
English (en)
Inventor
Wilfried Martin Braje
Sean Colm Turner
Andreas Haupt
Udo Lange
Herve Geneste
Karla Drescher
Liliane Unger
Ana-Lucia Jongen-Relo
Anton Bespalov
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PE20090950A1 publication Critical patent/PE20090950A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1,2,4-TRIAZIN-3,5-DIONA DE FORMULA (I) DONDE A ES UNA CADENA DE HIDROCARBURO (C4-C6) OPCIONALMENTE SUSTITUIDO CON METILO; R1 ES H, ALQUILO(C1-C3) O ALQUILO FLUORADO (C1-C3); R2 ES H, HALOGENO, CN, ALQUILO(C1-C3), ENTRE OTROS; R3 ES ALQUILO(C4-C6) O CICLOALQUILO(C3-C6); R4 ES ALQUILO(C1-C6), CICLOALQUILO(C3-C6), ALQUILO FLUORADO (C1-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-{4-[4-(2-TERT-BUTIL-6-TRIFLUOROMETIL-PIRIMIDIN-4-IL)-PIPERAZIN-1-IL]-BUTIL}-2H-[1,2,4]TRIAZIN-3,5-DIONA, 2-{4-[4-(2-TERT-BUTIL-6-PROPIL-PIRIMIDIN-4-IL)-PIPERAZIN-1-IL]-BUTIL}-2H-[1,2,4]TRIAZIN-3,5-DIONA, 2-{4-[4-(2,6-DI-TERT-BUTIL-PIRIMIDIN-4-IL)-PIPERAZIN-1-IL]-BUTIL}-2H-[1,2,4]TRIAZIN-3,5-DIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE DOPAMINA D3 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, TRASTORNO BIPOLAR, NEFROPATIA DIABETICA
PE2008001865A 2007-11-02 2008-10-31 Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 PE20090950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02

Publications (1)

Publication Number Publication Date
PE20090950A1 true PE20090950A1 (es) 2009-08-08

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001865A PE20090950A1 (es) 2007-11-02 2008-10-31 Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3

Country Status (29)

Country Link
US (1) US8492540B2 (es)
EP (1) EP2217593B1 (es)
JP (1) JP5559694B2 (es)
KR (1) KR20100094491A (es)
CN (1) CN101932574B (es)
AR (1) AR069150A1 (es)
AT (1) ATE556069T1 (es)
AU (1) AU2008320814B2 (es)
BR (1) BRPI0818726A2 (es)
CA (1) CA2704533C (es)
CL (1) CL2008003253A1 (es)
CO (1) CO6280473A2 (es)
CR (1) CR11410A (es)
DO (1) DOP2010000126A (es)
EC (1) ECSP10010227A (es)
ES (1) ES2386691T3 (es)
HK (1) HK1146628A1 (es)
IL (1) IL205468A0 (es)
MX (1) MX2010004830A (es)
MY (1) MY154066A (es)
NZ (1) NZ585051A (es)
PA (1) PA8802101A1 (es)
PE (1) PE20090950A1 (es)
RU (1) RU2478633C2 (es)
TW (1) TWI463984B (es)
UA (1) UA99634C2 (es)
UY (1) UY31448A1 (es)
WO (1) WO2009056625A1 (es)
ZA (1) ZA201003593B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505753B2 (en) 2012-08-08 2016-11-29 The Johns Hopkins University Inhibitors of D-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
TW200510395A (en) * 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
US8202868B2 (en) * 2004-08-09 2012-06-19 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
AU2005311452A1 (en) * 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1

Also Published As

Publication number Publication date
UY31448A1 (es) 2009-05-29
US20100311755A1 (en) 2010-12-09
HK1146628A1 (en) 2011-06-24
JP2011502971A (ja) 2011-01-27
DOP2010000126A (es) 2010-06-15
CN101932574A (zh) 2010-12-29
CA2704533A1 (en) 2009-05-07
JP5559694B2 (ja) 2014-07-23
MY154066A (en) 2015-04-30
AR069150A1 (es) 2009-12-30
AU2008320814B2 (en) 2013-07-11
MX2010004830A (es) 2010-10-20
CR11410A (es) 2010-09-13
CA2704533C (en) 2016-09-06
AU2008320814A1 (en) 2009-05-07
CO6280473A2 (es) 2011-05-20
TWI463984B (zh) 2014-12-11
EP2217593A1 (en) 2010-08-18
UA99634C2 (ru) 2012-09-10
NZ585051A (en) 2012-03-30
ES2386691T3 (es) 2012-08-27
CL2008003253A1 (es) 2009-11-13
BRPI0818726A2 (pt) 2015-04-22
RU2478633C2 (ru) 2013-04-10
US8492540B2 (en) 2013-07-23
IL205468A0 (en) 2010-12-30
EP2217593B1 (en) 2012-05-02
ATE556069T1 (de) 2012-05-15
TW200927132A (en) 2009-07-01
WO2009056625A1 (en) 2009-05-07
CN101932574B (zh) 2014-07-23
KR20100094491A (ko) 2010-08-26
ZA201003593B (en) 2011-02-23
RU2010122337A (ru) 2011-12-10
ECSP10010227A (es) 2010-08-31
PA8802101A1 (es) 2009-08-26

Similar Documents

Publication Publication Date Title
PE20140934A1 (es) Derivados de pirazol
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
AR061644A1 (es) Derivados de benzofurano
PE20091901A1 (es) Activadores de glucoquinasa
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20142282A1 (es) Nuevos derivados de aril-quinolina
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20130155A1 (es) Derivados de ariletinilo
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
PE20090950A1 (es) Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3
PE20070586A1 (es) Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
PE20091527A1 (es) Derivados de piridazinona
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
PE20090899A1 (es) Derivados de aminobenceno como moduladores del receptor de androgeno
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed